

Haematologica. 2022 Jun 1;107(6):1239-1242

PMID: 35642484

DOI: 10.3324/haematol.2022.280920

Introduction to a review series on the treatment of thrombocytopenic disorders: something old, something new

Francesco Rodeghiero

Thrombocytopenia may be a major component of several disorders, exposing patients to an increased risk of bleeding and/or heralding more complex, but often underestimated, clinical scenarios. In a series of reviews in *Haematologica*, leading authors comprehensively discuss the management of thrombocytopenia in three distinct clinical areas generally neglected and still lacking specific treatments.¹⁻³ Inherited thrombocytopenias,¹ drug-induced immune thrombocytopenia² and chemotherapy-induced thrombocytopenia³ were chosen as illustrative epitomes. In the review on drug-induced immune thrombocytopenia, three subsections expand beyond classical cases of drug-associated thrombocytopenia to include, in addition to the well-known heparin-induced thrombocytopenia, two rare complications recently reported in association with vaccination against coronavirus disease 2019 (COVID-19) – vaccine-induced thrombotic thrombocytopenia⁴ and vaccine-associated immune thrombocytopenia.

Link all'articolo: <https://pubmed.ncbi.nlm.nih.gov/35642484/>